Clinical Outcomes of Ayurvedic Management in Hunter Syndrome: A Case Report

Abstract

Introduction: Hunter Syndrome, otherwise called Mucopolysaccharidosis Type II, is a rare X- linked Lysosomal Storage disorder, occurring due to the deficiency of Iduronate-2-sulfatase enzyme (I2S). This leads to impaired Glycosaminoglycans catabolism (GAGs), resulting in the pathological accumulation of Heparan sulfate and Dermatan sulfate in multiple tissues and organs. It manifests as a progressive, multisystemic, genetic metabolic disorder. In Ayurveda, Hunter Syndrome is correlated with Sahaja Vyadhi (genetic disease) arising due to genetic defects, manifesting with persistent, impaired metabolism, coarse facies, hirsutism, multiple joint contractures, short stature, hyperactivity, and subnormal cognitive development. Methods: A single case study of a 4-year-old boy with Hunter syndrome was evaluated to analyze the efficacy of ayurvedic therapies on the quality of life. The child was managed with symptomatic treatment and rejuvenation therapy. Oral medicines were targeted for Deepana (appetite stimulant), and Pachana (digestive) to rectify metabolism and to improve cognitive abilities. Procedure-based therapies were targeted to treat physical impairments. Results: After five months of exclusive oral medications and one course of external therapies, the child showed improvement in metabolic activity, cognitive abilities and joint mobility, marking overall well-being and enhanced quality of life. Conclusion: Hunter syndrome is an early onset, progressive disorder, with high morbidity and poor life expectancy, making it a Sahaja Vata Pradhana Tridoshaja Vyadhi. Early diagnosis, genetic counseling, and an integrative approach combining contemporary and traditional therapeutic strategies may reduce mortality and improve long- term health outcomes in affected children.